New agents active against Mycobacterium avium complex selected by molecular topology: A virtual screening method

Journal of Antimicrobial Chemotherapy

Volumn 53, Issue 1, 2004, Pages 65-73

  García García, Ángeles ^a   Gálvez, Jorge ^a   de Julián Ortiz, Jesus Vicente ^b   García Domenech, Ramón ^a   Muñoz, Carlos ^c   Guna, Remedios ^a,c   Borrás, Rafael ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

MAC; QSAR studies; Topological indices

Indexed keywords

ACIFRAN; ACIPIMOX; AFLATOXIN B1; ANTIINFECTIVE AGENT; AZITHROMYCIN; BENZALKONIUM CHLORIDE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DIHYDROSTREPTOMYCIN; ENVIOMYCIN; ETHAMBUTOL; FRAMYCETIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; PAROMOMYCIN; PENTAMIDINE; RESERPINE; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TIOCARLIDE; TRIFLUOPERAZINE; TUBERIN; UNINDEXED DRUG; VIOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; DISCRIMINANT ANALYSIS; DRUG CLASSIFICATION; DRUG DETERMINATION; DRUG SCREENING; DRUG STRUCTURE; IN VITRO STUDY; LINEAR REGRESSION ANALYSIS; LINEAR SYSTEM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MYCOBACTERIUM AVIUM COMPLEX; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0347287021     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh014     Document Type: Article

References (37)

1. Yajko, D. M., Nassos, P. S. & Hadley, W. K. (1987). Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrobial Agents and Chemotherapy 31, 1579-84.
2. Hoffner, S. E., Gezelius, L. & Olsson-Liljequist, B. (1997). In vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 40, 885-8.
3. Tomioka, H. (2002). Prospects for development of new antituberculous drug. Kekkaku 77, 573-84.
4. Koketsu, M., Tanaka, K., Takenaka, Y. et al. (2002). Synthesis of 1,3-thiazine derivates and their evaluation as potential antimycobacterial agents. European Journal of Pharmaceutical Sciences 15, 307-10.
5. Sandbhor, U., Padhye, S., Billington, D. et al. (2002). Metal complexes of carboxamidrazone analogs as antitubercular agents. Synthesis, X-ray crystal-structures, spectroscopic properties and antimycobacterial activity against Mycobacterium tuberculosis H(37). Journal of Inorganic Biochemistry 90, 127-36.
6. Kier, L. B. & Hall, L. H. (1986). Molecular Connectivity in Structure-Activity Analysis, pp. 225-46. John Wiley & Sons, Letchworth, UK.
7. Balaban, A. T. (1983). Topological indices based on topological distances in molecular graphs. Pure and Applied Chemistry 55, 199-206.
8. Estrada, E., Peña, A. & García-Domenech, R. (1998). Designing sedative/hypnotic compounds from a novel substructural graph-theoretical approach. Journal of Computer-Aided Molecular Design 12, 583-95.
9. Kier, L. B., Murray, W. J., Randić, M. et al. (1976). Molecular Connectivity V: connectivity series concept applied to density. Journal of Pharmaceutical Sciences 65, 1226-30.
10. Balaban, A. T. (1982). Highly discriminating distance based topological index. Chemical Physics Letters 89, 399-404.
11. Gálvez, J., García-Domenech, R., de Julián-Ortiz, J. V. et al. (1994). Topological approach to analgesia. Journal of Chemical Information and Computer Sciences 34, 1198-203.
12. Ríos-Santamarina, I., García-Domenech, R., Gálvez, J. et al. (1998). New bronchodilators selected by molecular topology. Bioorganic and Medicinal Chemistry Letters 8, 477-82.
13. Casabán, E., Antón-Fos, G. M., Gálvez, J. et al. (1999). Search of new antihistaminic compounds by molecular connectivity. Quantitative Structure-Activity Relationships 18, 35-42.
14. de Julián-Ortiz, J. V., Gálvez, J., Muñoz-Collado, C. et al. (1999). Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds. Journal of Medicinal Chemistry 42, 3308-14.
15. de Gregorio-Alapont, C., García-Domenech, R., Gálvez, J. et al. (2000). Molecular topology: a useful tool for the search of new antibacterials. Bioorganic and Medicinal Chemistry Letters 10, 2033-6.
16. García-Domenech, R., Catalá, A. I., García-García, A. et al. (2002). QSAR by molecular topology of 2,4-dihydroxythiobenzanilides: a virtual screening approach to optimize the antifungal activity. Indian Journal of Chemistry 41B, 2376-84.
17. Gozalbes, R., Brun-Pascaud, M., García-Domenech, R. et al. (2000). Prediction of quinolone activity against Mycobacterium avium by molecular topology and virtual computational screening. Antimicrobial Agents and Chemotherapy 44, 2764-70.
18. Burke, A. & Cunha, M. D. (1988). Aminoglucósidos: papel actual en la terapia antimicrobiana. Pharmacotherapy 8, Suppl. 6, 334-50.
19. Fernandes, P. B., Hardy, D. J., McDaniel, D. et al. (1989). In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrobial Agents and Chemotherapy 33, Suppl. 9, 1531-4.
20. Perronne, C., Gikas, A., Truffot-Pernot, C. et al. (1991). Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of M. avium complex within human macrophages. Antimicrobial Agents and Chemotherapy 35, 1356-9.
21. Jacobs, M. R. (1995). Activity of quinolones against mycobacteria. Drugs 49, Suppl. 2, 67-75.
22. García-Sánchez, J. E., López, R. & Prieto, J. (1999). Antimicrobianos en medicina, pp. 449-55. Sociedad Española de Quimioterapia. Prous Science, S.A.
23. Gillespie, S. H. & Billington, O. (1999). Activity of moxifloxacin against mycobacteria. Journal of Antimicrobial Chemotherapy 44, 393-5.
24. Gálvez, J., García-Domenech, R., de Julián-Ortiz, J. V. et al. (1995). Topological approach to drug design. Journal of Chemical Information and Computer Sciences 35, 272-84.
25. Gálvez, J., García-Domenech, R., Salabert, M. T. et al. (1994). Charge indices. New topological descriptors. Journal of Chemical Information and Computer Sciences 34, 520-5.
26. Gálvez, J., García-Domenech, R., de Gregorio-Alapont, C. et al. (1996). Pharmacological distribution diagrams: a tool for the new drug design. Journal of Molecular Graphics and Modelling 14, 272-6.
27. Furnival, G. M. & Wilson, R. W. (1974). Regressions by leaps and bounds. Technometrics 16, 499-511.
28. Hocking, R. R. (1972). Criteria for selection of a subset regression: which one should be used? Technometrics 14, Suppl. 4, 967-70.
29. Allen, D. M. (1974). The relationship between variable selection and data augmentation and a method for prediction. Technometrics 16, 125-7.
30. Wold, S. & Eriksson, L. (1995). Statistical validation of QSAR results. In Chemometric Methods in Molecular Design (Van de Waterbeemd, H., Ed), vol. 2, pp. 309-18. VCH, New York.
31. Heifets, L. (1996). Susceptibility testing of Mycobacterium avium complex isolates. Antimicrobial Agents and Chemotherapy 40, 1759-67.
32. Franzblau, S. G., Witzig, R. S., McLaughlin, J. C. et al. (1998). Rapid low technology MIC determination with clinical Mycobacterium isolates by using the microplate alamar blue assay. Journal of Clinical Microbiology 36, 362-6.
33. Heifets, L. B. (1996). Clinical mycobacteriology. Drug susceptibility testing. Clinics in Laboratory Medicine 16, Suppl. 3, 641-56.
34. Rikimaru, T., Kondo, M., Kondo, S. et al. (2000). Efficacy of common antiseptics against mycobacteria. International Journal of Tuberculosis and Lung Disease 4, 570-6.
35. Donald, P. R., Sirget, F. A., Kanyok, T. P. et al. (2000). Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy 44, Suppl. 12, 3285-7.
36. Gadre, D. V. & Talwar, V. (1999). In vitro susceptibility testing of Mycobacterium tuberculosis strains to trifluoperazine. Journal of Chemotherapy 11, Suppl. 3, 203-6.
37. Zhang, Y., Permar, S. & Sun, Z. (2002). Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. Journal of Medical Microbiology 51, Suppl. 1, 42-9.